Cagri peptide vs tirzepatide: compare how the amylin analog cagrilintide stacks up against tirzepatide in trials, dosing, side effects, and FDA status.
"Cagri peptide" is shorthand for cagrilintide, a long-acting amylin analog that is studied mostly as part of the combination drug CagriSema (cagrilintide plus semaglutide). Tirzepatide is a different drug — a single molecule that activates both GIP and GLP-1 receptors, sold as Mounjaro and Zepbound. No head-to-head trial has ever compared cagrilintide with tirzepatide, so every comparison today comes from separate studies, different mechanisms, and different regulatory status.
What "Cagri Peptide" Actually Means
Cagrilintide is a synthetic, long-acting version of amylin, a hormone your pancreas releases alongside insulin after meals. Amylin slows stomach emptying and signals fullness to the brain, which is why the amylin pathway became an attractive target for weight management.
Natural amylin breaks down quickly, so researchers modified the molecule with fatty acid chains to extend its half-life to roughly a week. That modification allows once-weekly subcutaneous dosing.
Cagrilintide is rarely studied alone in phase 3 trials. The headline product is CagriSema, a fixed-dose combination of cagrilintide and semaglutide, the GLP-1 used in Ozempic and Wegovy. Searches for cagrilintide vs tirzepatide tend to spike whenever a new CagriSema readout is published.
Gray-market sellers also offer cagrilintide as a lyophilized "research peptide" powder. Those vials are not FDA-approved, are not produced under pharmacy manufacturing standards, and are labeled for laboratory use only — not for human use.
How Tirzepatide Works
Tirzepatide is a dual agonist: one peptide chain that binds GIP receptors and GLP-1 receptors at the same time. GLP-1 slows digestion and reduces appetite, while GIP appears to influence how the body stores and uses fat.
Unlike cagrilintide, tirzepatide is FDA-approved. Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management in adults with obesity or with overweight plus at least one weight-related condition.
Approved dosing is a once-weekly injection, titrated from 2.5 mg up to a maximum of 15 mg per week. For the older debate of tirzepatide vs semaglutide which is better for weight loss, head-to-head SURPASS data in type 2 diabetes favored tirzepatide on both blood sugar and weight.
Cagrilintide vs Tirzepatide at a Glance
| Feature | Cagrilintide (cagri peptide) | Tirzepatide |
|---|---|---|
| Drug class | Long-acting amylin analog | Dual GIP/GLP-1 receptor agonist |
| Receptors targeted | Amylin and calcitonin receptors | GIP and GLP-1 |
| Most-studied form | CagriSema (with semaglutide) | Single molecule |
| FDA-approved brand | None | Mounjaro, Zepbound |
| Schedule and route | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Best reported phase 3 weight loss | About 22.7% at 68 weeks, combination and on-treatment | About 20.9% at 72 weeks, 15 mg, treatment-regimen estimand |
| Common side effects | Nausea, vomiting, diarrhea, injection-site reactions | Nausea, vomiting, diarrhea, constipation, fatigue |
What the Trials Show About Weight Loss
In the REDEFINE-1 trial, participants taking CagriSema lost an average of about 22.7% of their body weight at 68 weeks when the analysis counted people who stayed on treatment. Intent-to-treat results were lower, closer to 20%.
In SURMOUNT-1, adults taking tirzepatide 15 mg lost an average of about 20.9% of body weight at 72 weeks. Among participants who completed treatment on the highest dose, average loss was closer to 22.5%.
CagriSema and tirzepatide have produced similar average weight loss in separate phase 3 trials, but the two drugs have never been compared directly in the same study.
Cagrilintide on its own has been less impressive. A phase 2 trial of cagrilintide monotherapy reported roughly 10.8% weight loss at 26 weeks at the 2.4 mg dose, which is well below what tirzepatide monotherapy achieves.
If you are mapping next-generation options, cagrilintide vs retatrutide vs tirzepatide is the comparison that covers the triple-agonist landscape as well. Peptides that act on mitochondria, such as the pairing discussed in mots-c peptide vs tirzepatide, work through entirely different pathways and should not be grouped with appetite-hormone drugs.
Dosing, Cost, and Availability
Tirzepatide is available by prescription in single-dose pens and, through LillyDirect, in single-dose vials. List prices exceed $1,000 per month, though cash-pay vial programs and insurance coverage can lower the out-of-pocket cost substantially.
Cagrilintide has no approved dose and no approved product. Novo Nordisk has submitted CagriSema for regulatory review in the United States, but the combination remains investigational.
Compounded tirzepatide became far harder to obtain after the FDA resolved the shortage in late 2024, and mass-market compounding is no longer permitted for that molecule.
Injections marketed for fat loss, such as those discussed under lipo-c vs tirzepatide, are a separate category of products with different ingredients and far less clinical evidence behind them.
Side Effects and Safety Considerations
Both drug classes are associated with gastrointestinal side effects, especially during dose escalation. Nausea, vomiting, diarrhea, and constipation are the most frequently reported complaints, and they often ease after a few weeks.
Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Cagrilintide, like other amylin analogs, can also cause injection-site reactions and may increase the risk of low blood sugar when combined with insulin or sulfonylureas.
Neither drug is recommended during pregnancy, and both can worsen gallbladder disease or pancreatitis in susceptible people. Anyone considering either drug should talk to a licensed healthcare professional about their medical history, current medications, and contraindications.
The Bottom Line
- Cagrilintide is an amylin analog; tirzepatide is a GIP/GLP-1 dual agonist.
- Cagrilintide is not FDA-approved for any human use, while tirzepatide is approved for both type 2 diabetes and weight management.
- The similar weight-loss numbers for CagriSema and tirzepatide come from different trials and use different analysis methods, so they are not equivalent evidence.
- No direct trial has compared cagrilintide or CagriSema against tirzepatide.
- Unapproved research peptides sold online carry real risks of dosing errors, impurities, and sterility problems.
The word "cagri" refers to one peptide, not a finished product. CagriSema performs well in trials precisely because it pairs cagrilintide with semaglutide, and tirzepatide is a single molecule that hits two receptors. Until a head-to-head study exists, treating them as interchangeable would be a mistake.
Frequently Asked Questions
Is cagri peptide the same thing as cagrilintide?
Yes. "Cagri peptide" is shorthand for cagrilintide, a long-acting amylin analog developed by Novo Nordisk. It is being studied mainly in combination with semaglutide under the name CagriSema.
Is cagrilintide FDA-approved in the United States?
No. Cagrilintide has not been approved by the FDA, and there is no approved cagrilintide product on the U.S. market. CagriSema, the combination of cagrilintide and semaglutide, has been submitted for regulatory review but remains investigational.
Does cagrilintide or tirzepatide cause more weight loss?
No head-to-head trial has compared them. In separate phase 3 studies, CagriSema produced about 22.7% weight loss at 68 weeks on-treatment, while tirzepatide 15 mg produced about 20.9% at 72 weeks. Because the trials enrolled different participants and used different analysis methods, those figures cannot be treated as a direct comparison.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.